Banque Cantonale Vaudoise Acquires 5,534 Shares of Avantor, Inc. (NYSE:AVTR)

Banque Cantonale Vaudoise increased its position in shares of Avantor, Inc. (NYSE:AVTRFree Report) by 44.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 17,934 shares of the company’s stock after purchasing an additional 5,534 shares during the quarter. Banque Cantonale Vaudoise’s holdings in Avantor were worth $378,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. Amalgamated Bank lifted its holdings in Avantor by 4.8% during the 3rd quarter. Amalgamated Bank now owns 65,798 shares of the company’s stock worth $1,387,000 after purchasing an additional 2,997 shares during the last quarter. Boston Partners lifted its holdings in Avantor by 21.4% during the 3rd quarter. Boston Partners now owns 28,077,026 shares of the company’s stock worth $588,362,000 after purchasing an additional 4,948,951 shares during the last quarter. Robeco Schweiz AG lifted its holdings in Avantor by 8.1% during the 3rd quarter. Robeco Schweiz AG now owns 8,154,000 shares of the company’s stock worth $171,886,000 after purchasing an additional 607,500 shares during the last quarter. Chartwell Investment Partners LLC lifted its holdings in Avantor by 22.4% during the 3rd quarter. Chartwell Investment Partners LLC now owns 374,393 shares of the company’s stock worth $7,892,000 after purchasing an additional 68,537 shares during the last quarter. Finally, Quantbot Technologies LP lifted its holdings in Avantor by 264.7% during the 3rd quarter. Quantbot Technologies LP now owns 21,741 shares of the company’s stock worth $458,000 after purchasing an additional 15,780 shares during the last quarter. 89.04% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on AVTR shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $28.00 price objective on shares of Avantor in a report on Tuesday, January 9th. Morgan Stanley dropped their price objective on Avantor from $24.00 to $22.00 and set an “overweight” rating for the company in a report on Monday, October 30th. Barclays lifted their price objective on Avantor from $21.00 to $24.00 and gave the company an “overweight” rating in a report on Monday, December 11th. Wolfe Research started coverage on Avantor in a report on Wednesday, December 13th. They issued a “peer perform” rating for the company. Finally, The Goldman Sachs Group lifted their price objective on Avantor from $23.00 to $26.00 and gave the company a “buy” rating in a report on Thursday, December 7th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $24.55.

View Our Latest Research Report on Avantor

Avantor Trading Down 1.6 %

Shares of AVTR stock opened at $23.30 on Friday. The firm has a market capitalization of $15.76 billion, a P/E ratio of 43.15, a P/E/G ratio of 1.43 and a beta of 1.36. Avantor, Inc. has a twelve month low of $16.63 and a twelve month high of $25.25. The company has a quick ratio of 1.03, a current ratio of 1.60 and a debt-to-equity ratio of 1.04. The stock’s fifty day simple moving average is $22.34 and its 200 day simple moving average is $21.21.

About Avantor

(Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

See Also

Want to see what other hedge funds are holding AVTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avantor, Inc. (NYSE:AVTRFree Report).

Institutional Ownership by Quarter for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.